Hancock Whitney Corp Biogen Inc. Transaction History

Hancock Whitney Corp

$2.88 Billion
Q1 2024

A detailed history of Hancock Whitney Corp transactions in Biogen Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 2,147 shares of BIIB stock, worth $484,470. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,147

Previous 2,027 5.92%

Holding current value

$484,470

Previous $524,000 11.83%

% of portfolio

0.02%

Previous 0.02%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$212.02 - $267.71 $25,442 - $32,125	120 Added 5.92%	2,147 $462,000
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $31,385 - $37,779	-141 Reduced 6.5%	2,027 $524,000
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $12,918 - $14,580	-51 Reduced 2.3%	2,168 $557,000
Q2 2023 Nov 13, 2023	SELL	$275.25 - $318.06 $148,635 - $171,752	-540 Reduced 19.57%	2,219 $632,000
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $148,635 - $171,752	-540 Reduced 19.57%	2,219 $632,000

Q1 2023 Nov 13, 2023	BUY	$256.56 - $292.34 $19,498 - $22,217	76 Added 2.83%	2,759 $767,000
Q1 2023 May 16, 2023	BUY	$256.56 - $292.34 $19,498 - $22,217	76 Added 2.83%	2,759 $767,000
Q4 2022 Nov 13, 2023	BUY	$252.44 - $306.72 $117,132 - $142,318	464 Added 20.91%	2,683 $742,000
Q4 2022 Feb 03, 2023	SELL	$252.44 - $306.72 $55,789 - $67,785	-221 Reduced 7.61%	2,683 $743,000
Q3 2022 Oct 26, 2022	BUY	$194.69 - $268.46 $124,796 - $172,082	641 Added 28.33%	2,904 $775,000
Q2 2022 Aug 08, 2022	BUY	$187.54 - $223.02 $1,875 - $2,230	10 Added 0.44%	2,263 $462,000
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $55,418 - $69,824	-286 Reduced 11.26%	2,253 $474,000
Q4 2021 Jan 25, 2022	SELL	$223.92 - $287.77 $86,433 - $111,079	-386 Reduced 13.2%	2,539 $609,000
Q3 2021 Nov 04, 2021	SELL	$282.99 - $369.05 $160,455 - $209,251	-567 Reduced 16.24%	2,925 $828,000
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $6.54 Million - $10.5 Million	-25,237 Reduced 87.85%	3,492 $1.21 Million
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $916,893 - $1.07 Million	3,774 Added 15.12%	28,729 $8.04 Million
Q4 2020 Feb 09, 2021	SELL	$236.26 - $355.63 $1.6 Million - $2.41 Million	-6,768 Reduced 21.33%	24,955 $6.11 Million
Q3 2020 Nov 05, 2020	SELL	$264.77 - $305.71 $340,229 - $392,837	-1,285 Reduced 3.89%	31,723 $9 Million
Q2 2020 Jul 30, 2020	BUY	$258.66 - $342.55 $1.45 Million - $1.92 Million	5,600 Added 20.43%	33,008 $8.83 Million
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $3.22 Million - $4.08 Million	11,975 Added 77.59%	27,408 $8.67 Million
Q4 2019 Feb 06, 2020	BUY	$220.06 - $304.07 $13,423 - $18,548	61 Added 0.4%	15,433 $4.58 Million
Q3 2019 Oct 29, 2019	SELL	$217.44 - $243.88 $274,844 - $308,264	-1,264 Reduced 7.6%	15,372 $3.58 Million
Q2 2019 Aug 29, 2019	SELL	$219.29 - $241.72 $216,219 - $238,335	-986 Reduced 5.6%	16,636 $3.89 Million
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $28,389 - $44,403	-131 Reduced 0.74%	17,622 $4.17 Million
Q4 2018 Feb 15, 2019	SELL	$278.5 - $352.75 $132,844 - $168,261	-477 Reduced 2.62%	17,753 $5.34 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $5.35 Million - $7 Million	18,230 New	18,230 $6.44 Million

Others Institutions Holding BIIB

# of Institutions

1,047

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $32.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.

Account

Hancock Whitney Corp Biogen Inc. Transaction History